SCICLONE ANNOUNCES PRESENTATION OF ZADAXIN DATA

A A

SciClone Pharmaceuticals has announced the presentation of data from its Phase II hepatocellular carcinoma, or primary liver cancer, trial at the Shanghai-Hong Kong International Liver Congress.

The company reported these data in late 2005, which showed a median survival of 994 days for the 12 patients who received Zadaxin plus trans-arterial chemoembolization (TACE), compared with a median survival of only 399 days for the 13 patients who only received TACE.